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Clinical Case Report

OPEN

Carney complex with PRKAR1A gene mutation
A case report and literature review
Qiuli Liu, MDa, Dali Tong, MD, PhDa, Gaolei Liu, MDa, Yuting Yi, BSb, Dianzheng Zhang, PhDc,
Jun Zhang, MD, PhDa, Yao Zhang, MD PhDa, Zaoming Huang, MDa, Yaoming Li, MD, PhDa,
∗
Rongrong Chen, MD, PhDb, Yanfang Guan, BSb, Xin Yi, MD, PhDb, Jun Jiang, MD, PhDa,
Abstract
Rationale: Carney complex (CNC) is a multiple neoplasia syndrome with autosomal dominant inheritance. CNC is characterized by

the presence of myxomas, spotty skin pigmentation, and endocrine overactivity. No direct correlation has been established between
disease-causing mutations and phenotype.
Patient concerns: A 16-year-old boy was admitted because of excessive weight gain over 3 years and purple striae for 1 year.
Physical examination revealed Cushingoid features and spotty skin pigmentation on his face, lip, and sclera.
Diagnoses: The patient was diagnosed as Carney complex.
Interventions: the patient underwent right adrenalectomy and partial adrenalectomy of the left adrenal gland.
Outcome: Results of imaging showed bilateral adrenal nodular hyperplasia, multiple microcalciﬁcations of the bilateral testes, and

compression fracture of the thoracolumbar spine. Histopathological results conﬁrmed multiple pigmented nodules in the adrenal glands.
DNA sequencing revealed a nonsense mutation in the gene encoding regulatory subunit type 1-alpha of protein kinase A (PRKAR1A;
c.205C > T). After the second adrenalectomy, the Cushingoid features disappeared, and cortisol levels returned to normal.
Lessons: Carney complex is a rare disease that lacks consistent genotype–phenotype correlations. Our patient, who carried a
germline PRKAR1A nonsense mutation (c.205C > T), clinical features included spotty skin pigmentation, osteoporosis, and primary
pigmented nodular adrenal disease. Adrenalectomy is the preferred treatment for Cushing syndrome due to primary pigmented
nodular adrenal disease.
Abbreviations: ACTH = adrenocorticotropic hormone, CNC = Carney complex, IRB = institutional review board, LCCST = large-cell
calcifying Sertoli cell tumor, PKA = protein kinase A, PPNAD = primary pigmented nodular adrenal disease, RIa = 1-a regulatory subunit.
Keywords: adrenalectomy, Carney complex, Cushing syndrome, PRKAR1A, rare diseases

area, and mucosa.[3] The most common noncutaneous lesions found
in CNC are cardiac myxomas (affecting 20–40% of patients), which
are responsible for >50% of CNC-related mortality.[4–6]
CNC is a genetically heterogeneous disease, with >70%
patients with CNC carrying mutations of the PRKAR1A gene,[5]
which encodes the 1-a regulatory subunit (RIa) of the cAMPdependent protein kinase A (PKA) and functions as a tumor
suppressor gene.[7] Pathogenic PRKAR1A mutations include
single base substitutions, small (15 bp) deletions/insertions,
combined rearrangements, and large deletions.[8–10] More than
125 PRKAR1A gene mutations have been identiﬁed; however,
linking genotype to phenotype has been challenging.[11] Although
previous studies [5,9,10,12–15] have demonstrated associations
between speciﬁc mutations and CNC manifestations, only 3
pathogenic variants (c.82C>T, c.491_492delTG, and c.709–
2_709–7 delATTTTT) have been identiﬁed in >3 unrelated
pedigrees.[5,7,13] The other mutations are unique (present in a
single kindred). To better understand genotype–phenotype
relationships in this rare heterogeneous disease, it is essential
to describe clinical features associated with speciﬁc mutations.
Here we present a case of CNC with a known germline
PRKAR1A nonsense mutation (c.205C>T) [5]; however, the
phenotype associated with this mutation has not yet been
established. Our results indicate that this PRKAR1A mutation
may be associated with increased pigmentation on the face, lip,
and sclera; osteoporosis resulting in compression fracture; and
primary pigmented nodular adrenal disease (PPNAD)-associated
Cushing syndrome.

1. Introduction
Carney complex (CNC) is a multiple neoplasia syndrome with an
autosomal dominant inheritance.[1] The clinical manifestations of
CNC vary widely but may include myxomas of the heart, skin, and
other tissues and multiple other endocrine and nonendocrine
neoplasms including pituitary tumors, adrenocortical tumors,
thyroid neoplasms, psammomatous melanotic schwannomas,
testicular tumors, breast tumors, ovarian lesions, and bone lesions.[2]
More than 80% of CNC patients develop spotty skin pigmentation
or skin growths, which typically appear early in life and may be
located anywhere on the body, typically on the face, lips, genital
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Figure 1. Patient characteristics before and after adrenalectomies. (A) Cushingoid features include moon face, central obesity, and purple striae of the bilateral
axillary and lower abdomen before the operations. (B) Cushingoid features are decreased after left and right adrenalectomies. (C–E) Spotty skin pigmentation
(indicated by red arrows) on the face (C), lip (D), and sclera (E).

2. Case report

central obesity, and purple striae of the bilateral axilla and lower
abdomen) (Fig. 1A), and spotty skin pigmentation on the face, lip,
and sclera (Fig. 1C–E). Laboratory ﬁndings revealed hypercortisolism (Table 1). After low- and high-dose dexamethasone
suppression tests, cortisol levels were still high (462.9 and 828.3

A 16-year-old boy was admitted to our department because of
excessive weight gain for 3 years and purple striate for 1 year. His
weight was 60 kg, and height was 1.2 m. Physical examination
revealed typical Cushingoid features (moon face, buffalo hump,
Table 1
Laboratory parameters of the patient.
Hormone (reference range)
Cortisol 8, ng/mL (50–280 ng/mL)
Cortisol 16, ng/mL (20–140 ng/mL)
Cortisol 24, ng/mL (10–120 ng/mL)
ACTH 8, pg/mL (5.08–32.8 pg/mL)
ACTH 16, pg/mL (10.7–30.5 pg/mL)
ACTH 24, pg/mL (5–15 pg/mL)
Testosterone, ng/mL (1.75–7.81 ng/mL)
Estradiol, pg/mL (20–47 ng/mL)
Luteinizing hormone, mIU/mL (1.24–8.62 mIU/mL)
Follicle-stimulating hormone, mIU/mL (1.27–19.26 mIU/mL)
Prolactin, ng/mL (2.64–13.13 ng/mL)
Growth hormone, mIU/L (0.5–13 mIU/L)

On admission

After ﬁrst adrenalectomy

After second adrenalectomy

310
296
259
5.88
10
5.51
0.33
<20
0.85
0.74
13.61
0.1

318
240
351
12.6
14.72
6.69
–
–
–
–
–
–

56
134
74
8.57
6.32
7.72
–
–
–
–
–
–

ACTH = adrenocorticotropin.
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Figure 2. Results of imaging, histopathology, and DNA sequencing. Adrenal computed tomography scan showed bilateral adrenal nodular hyperplasia (A and B).
Ultrasonography demonstrated multiple microcalciﬁcations of the bilateral testes (C and D). (E) Hematoxylin and eosin staining of the adrenal tissue revealed multiple
pigmented nodules. (F) Sequencing of DNA extracted from peripheral leukocytes identiﬁed a heterozygous C>T substitution in PRKAR1A exon 3 (indicated by the
red arrow).

Bidirectional DNA sequence analysis of the PRKAR1A gene
identiﬁed a known CNC-causing germline mutation (c.205C>T)
in exon 3 (Fig. 2F) and a second mutation (c.34 G>T) in the
intron preceding exon 9.

nmol/L, respectively), indicating adrenocorticotropic hormone
(ACTH)-independent Cushing syndrome. His grandparents have
no relevant disease, and his parents died early with unknown cause.
Adrenal computed tomography showed bilateral adrenal
nodular hyperplasia (Fig. 2A and B). Ultrasonography showed
a normal thyroid but multiple microcalciﬁcations of the bilateral
testes (Fig. 2C and D), suggesting large-cell calcifying Sertoli cell
tumor (LCCST). Considering the young age and the will of the
patient, the needle biopsy of the testes was not conducted to
conﬁrm the LCCST. However, testicular ultrasound is conducted
every 6 month to monitor the lesions. Results of magnetic
resonance imaging showed a pituitary normal but a compression
fracture of the thoracolumbar spine (T5–T12 and L1).
Echocardiography did not reveal any cardiac myxomas.
On February 19, 2017, the patient underwent right adrenalectomy via retroperitoneal laparoscopy; however, cortisol levels did
not normalize (Table 1). On March 1, 2017, the patient
underwent partial adrenalectomy of the left adrenal gland.
Histopathology ﬁndings of multiple pigmented nodules substantiated the diagnosis of PPNAD (Fig. 2E). After the second
adrenalectomy, the Cushingoid features disappeared (Fig. 1B),
and cortisol levels returned to normal (Table 1).

3. Discussion
In this study, we describe a patient with patient typical features of
CNC such as spotty skin pigmentation on the face, lip, and sclera;
osteoporosis resulting in compression fracture; and PPNADassociated Cushing syndrome. DNA sequencing identiﬁed a
known pathogenic mutation of PRKAR1A. Taken together, our
patient met the criteria for the diagnosis of CNC [2]: (1) spotty
pigmentation with the typical distribution (face, lip, and sclera);
(2) osteoporotic bone changes due primarily to glucocorticoid
excess, which accelerates bone resorption and decreases intestinal
calcium absorption and bone formation [16] (3); probable
LCCST, as demonstrated by ultrasonography of the bilateral
testes, which revealed multiple microcalciﬁcations; and (4)
Cushing syndrome, which may be ACTH-dependent or
ACTH-independent (e.g., caused by PPNAD, as in our patient).
CNC has diverse clinical manifestations, which typically develop
over a period of years.[2] Mutations in PRKAR1A appear to be the
most common cause of CNC. Patients carrying PRKAR1A
mutations have more severe disease, with earlier presentation
and higher frequency of myxomas, thyroid, and gonadal tumors,
schwannomas, and lentigines compared withPRKAR1A-negative
patients.[5,17] In a small number of PRKAR1A missense mutations,

2.1. Genetic analysis
Peripheral blood was collected after obtaining informed consent
from the patient’s grandparents. DNA was extracted from
leukocytes and ampliﬁed by the polymerase chain reaction.
3
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[6] Boikos SA, Stratakis CA. Carney complex: the ﬁrst 20 years. Curr Opin
Oncol 2007;19:24–9.
[7] Kirschner LS, Carney JA, Pack SD, et al. Mutations of the gene encoding
the protein kinase A type I-alpha regulatory subunit in patients with the
Carney complex. Nat Genet 2000;26:89–92.
[8] Salpea P, Horvath A, London E, et al. Deletions of the PRKAR1A locus at
17q24.2-q24.3 in Carney complex: genotype–phenotype correlations
and implications for genetic testing. J Clin Endocrinol Metab 2014;99:
E183–8.
[9] Horvath A, Bertherat J, Groussin L, et al. Mutations and polymorphisms
in the gene encoding regulatory subunit type 1-alpha of protein kinase A
(PRKAR1A): an update. Hum Mutat 2010;31:369–79.
[10] Horvath A, Bossis I, Giatzakis C, et al. Large deletions of the PRKAR1A
gene in Carney complex. Clin Cancer Res 2008;14:388–95.
[11] Anselmo J, Medeiros S, Carneiro V, et al. A large family with Carney
complex caused by the S147G PRKAR1A mutation shows a unique
spectrum of disease including adrenocortical cancer. J Clin Endocrinol
Metab 2012;97:351–9.
[12] Groussin L, Kirschner LS, Vincent-Dejean C, et al. Molecular analysis of
the cyclic AMP-dependent protein kinase A (PKA) regulatory subunit 1A
(PRKAR1A) gene in patients with Carney complex and primary
pigmented nodular adrenocortical disease (PPNAD) reveals novel
mutations and clues for pathophysiology: augmented PKA signaling is
associated with adrenal tumorigenesis in PPNAD. Am J Hum Genet
2002;71:1433–42.
[13] Groussin L, Horvath A, Jullian E, et al. A PRKAR1A mutation associated
with primary pigmented nodular adrenocortical disease in 12 kindreds. J
Clin Endocrinol Metab 2006;91:1943–9.
[14] Meoli E, Bossis I, Cazabat L, et al. Protein kinase A effects of an
expressed PRKAR1A mutation associated with aggressive tumors.
Cancer Res 2008;68:3133–41.
[15] Greene EL, Horvath AD, Nesterova M, et al. In vitro functional studies of
naturally occurring pathogenic PRKAR1A mutations that are not subject
to nonsense mRNA decay. Hum Mut 2008;29:633–9.
[16] Papanastasiou L, Fountoulakis S, Voulgaris N, et al. Identiﬁcation of a
novel mutation of the PRKAR1A gene in a patient with Carney complex
with signiﬁcant osteoporosis and recurrent fractures. Hormones
2016;15:129–35.
[17] Stratakis CA, Carney JA, Lin JP, et al. Carney complex, a familial
multiple neoplasia and lentiginosis syndrome. Analysis of 11 kindreds
and linkage to the short arm of chromosome 2. J Clin Invest
1996;97:699–705.
[18] Groussin L, Jullian E, Perlemoine K, et al. Mutations of the PRKAR1A
gene in Cushing’s syndrome due to sporadic primary pigmented nodular
adrenocortical disease. J Clin Endocrinol Metab 2002;87:4324–9.
[19] Pereira AM, Hes FJ, Horvath A, et al. Association of the M1V
PRKAR1A mutation with primary pigmented nodular adrenocortical
disease in two large families. J Clin Endocrinol Metab 2010;95:338–42.

the mRNA escapes nonsense-mediated decay, and the R I-a mutant
proteins are associated with a more severe phenotype.[14,15] Two
PRKAR1A mutations (c.709–7del6 and M1V c.1A>G/p.M1V
substitution) are associated with low penetrance, early-life isolated
PPNAD, and Cushing syndrome.[18,19] However, in most cases,
genotype cannot predict phenotype or penetrance. Therefore, it is
necessary to describe clinical features associated with speciﬁc
mutations. According to our case presentation, the mutation (c.
205 C>T) in our case is inclined to cause pigmented spots,
osteoporosis, as well as PPNAD.
In conclusion, we have identiﬁed a reported PRKAR1A
nonsense mutation (c.205C>T) in a sporadic case of CNC
characterized by the spotty skin pigmentation, osteoporosis
resulting in compression fracture, and PPNAD-associated
Cushing syndrome. The description of clinical features of this
patient adds to our knowledge of CNC and PRKAR1A
mutations. The ability to recognize CNC is important for early
diagnosis and prevention of severe complications. PRKAR1A
mutation analysis should be conducted as soon as possible in
patients with suspected CNC.
3.1. Compliance with ethical standards
The institutional review board (IRB) of Daping Hospital of Third
Military Medical University waived IRB approval for the study.
Written informed consent was obtained from the patient for the
use of medical records and related images.
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